8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
Taisho Pharmaceutical has submitted an application for approval to manufacture and market the anti-TNFα Nanobody therapeutic ozoralizumab to the Ministry of Health, Labor and Welfare (MHLW) for the planned indication of rheumatoid arthritis (RA), which is to-date inadequately managed by the current available treatments. 23 March 2021
The US Food and Drug Administration has approved a label update for Merck & Co’s blockbuster checkpoint blocker, targeting advanced esophageal or gastroesophageal (GEJ) cancer. 23 March 2021
Californian aging specialist CohBar is using mitochondrial science to treat diseases, but chief executive Steven Engle doesn’t rule out offering a “cure for ageing” at some point. 23 March 2021
US oral peptides specialist Chiasma’s shares were up 13% at $3.89 pre-market today, after the company announced the presentation of new positive clinical data from its MPOWERED Phase III trial of Mycapssa (octreotide) at the Endocrine Society’s annual meeting, ENDO 2021, being held virtually March 20-23, 2021. 23 March 2021
Top-line data from a trial testing an antibody cocktail in non-hospitalized people with the novel coronavirus show a reduction in the risk of hospitalization or death by 70%. 23 March 2021
The odds for and against betting on Provention Bio’s teplizumab, which is being studied in the prevention of type 1 diabetes (T1D) among at-risk patients, have been assessed. 22 March 2021
US biotech VistaGen Therapeutics has presented data highlighting the proposed mechanism of action (MOA) of its Phase III investigational drug candidate, PH94B nasal spray at the Anxiety and Depression Association of America’s 2021 Virtual Annual Conference. 22 March 2021
London-listed Finnish biopharma company Faron Pharmaceuticals saw its shares rise as much as 20% to 377 pence this morning, after it said its cancer drug had reduced risk of death by 88% in a clinical trial. 22 March 2021
Roche has announced that the Phase III IMpower010 study of Tecentriq (atezolizumab) met its primary endpoint of disease-free survival (DFS) at the interim analysis. 22 March 2021
Germany-based biotech Evotec has entered into a multi-RNA target alliance with Takeda Pharmaceutical with the aim of discovering and developing RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches. 22 March 2021
A long-awaited USA-based Phase III trial of Covid-19 Vaccine AstraZeneca has proved successful, paving the way for its use in the country. 22 March 2021
US biotech Clovis Oncology saw its shares leap as much as 60% to $8.5 on Friday, after the company announced that its Rubraca (rucaparib) treatment for ovarian cancer met its primary endpoint in a Phase III trial 20 March 2021
UK-based Oxford Biomedica, a gene and cell therapy group, announced today that French pharma major Sanofi has given notice that it intends to terminate the collaboration and license agreement for process development and manufacturing of lentiviral vectors to treat hemophilia. 19 March 2021
USA-based oncology specialist Idera Pharmaceuticals has been dealt a severe blow by a negative result from the pivotal ILLUMINATE-301 trial. 19 March 2021
The US Food and Drug Administration has approved Arcalyst (rilonacept) injection to treat recurrent pericarditis and reduce the risk of recurrence in adults and children 12 years and older. 19 March 2021
Marking a second disappointment for Incyte in the novel coronavirus setting, the company announced results from the Phase III DEVENT study evaluating the efficacy and safety of Jakafi (ruxolitinib) 5mg and 15mg plus standard of care (SoC) versus SoC in patients on mechanical ventilation with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS), a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. 19 March 2021
Another major manufacturing investment from Japanese conglomerate Fujifilm Corp will significantly up its presence in cell culture production for biologic therapies. 19 March 2021
In just a little over a week, Selexis has announced three agreements with drug developers – Pandion, BITT and now UK biotech firm SpyBiotech – that are levering Selexis’ SUREtechnology Platform to develop a variety of biologics and vaccines. 19 March 2021
Japan’s largest drugmaker Takeda Pharmaceutical has been an active deal-maker, particularly since its $62 billion buy of Shire, both acquiring and selling assets, and today continued that trend. 18 March 2021
US biotech Gilead Sciences and Danish diabetes specialist Novo Nordisk have announced that the companies have expanded their clinical collaboration in non-alcoholic steatohepatitis (NASH). 18 March 2021
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.